Invenomic Capital Exits $24M Haemonetics Stake Amid MedTech Underperformance
Key Takeaways
- Invenomic Capital Management has fully liquidated its $24.29 million position in Haemonetics Corporation, signaling a shift away from the underperforming medical device maker.
- The exit comes as Haemonetics shares have lagged the broader market, dropping 9% over the past year while the fund rotates capital into diversified healthcare and technology plays.
Mentioned
Key Intelligence
Key Facts
- 1Invenomic Capital Management sold 498,317 shares of Haemonetics (HAE), valued at $24.29 million.
- 2The exit reduced HAE from 1.2% of the fund's 13F AUM to zero.
- 3Haemonetics shares fell 9% over the past year, significantly underperforming the S&P 500's 16% gain.
- 4Viatris (VTRS) has emerged as the fund's top holding with a $69.64 million position.
- 5Haemonetics' stock price was recorded at $58.58 at the time of the reporting.
| Metric | |||
|---|---|---|---|
| Fund Position Value | $0 (Exited) | $69.64M | $58.66M |
| Portfolio Weight | 0.0% | 3.4% | 2.8% |
| Industry Focus | Blood/Plasma Mgmt | Diversified Pharma | Dental Technology |
Who's Affected
Analysis
The full liquidation of Invenomic Capital Management’s stake in Haemonetics Corporation (HAE) marks a significant shift in institutional sentiment for the medical technology sector. According to a February 17, 2026, SEC filing, the fund sold its entire position of 498,317 shares, which was previously valued at $24.29 million. This move represents a complete exit from a position that once accounted for 1.2% of Invenomic’s 13F assets under management (AUM). The timing of this exit is particularly noteworthy as Haemonetics has struggled to maintain pace with the broader market, posting a 9% decline over the past year while the S&P 500 gained approximately 16%.
Haemonetics is a cornerstone of the blood and plasma management industry, providing automated collection devices, hemostasis analyzers, and integrated software solutions. Its business model relies heavily on the recurring revenue generated from disposables used in plasma centers and hospitals. While the plasma collection market has seen a post-pandemic recovery, Haemonetics has faced intensifying competition and shifting hospital capital expenditure priorities. The decision by Invenomic to exit entirely suggests a lack of confidence in the company’s near-term ability to reverse its underperformance or a strategic pivot toward higher-growth or more stable value plays within the healthcare space.
Viatris, a global healthcare company formed through the merger of Mylan and Upjohn, now represents the fund’s largest holding at $69.64 million, or 3.4% of AUM.
The capital freed from the Haemonetics exit appears to have been redistributed into other sectors, with Invenomic’s top holdings now dominated by Viatris (VTRS), Global Payments (GPN), and Dentsply Sirona (XRAY). Viatris, a global healthcare company formed through the merger of Mylan and Upjohn, now represents the fund’s largest holding at $69.64 million, or 3.4% of AUM. This shift indicates a preference for diversified pharmaceutical and dental technology assets over the specialized blood management niche occupied by Haemonetics. Dentsply Sirona, which now makes up 2.8% of the fund’s AUM, suggests that Invenomic still sees value in medical devices but is prioritizing companies with broader exposure to elective procedures and dental health.
What to Watch
For investors, the Invenomic exit serves as a cautionary signal regarding the "K-shaped" recovery within the medical device industry. While some segments, such as cardiovascular and orthopedic devices, have thrived as surgical volumes normalized, others like blood management have faced more complex headwinds. Haemonetics’ stock price of $58.58 reflects a valuation that has failed to capture the market's enthusiasm, likely due to concerns over margin pressure in its plasma business and the slow adoption of its newer software platforms. The company’s strategy of delivering integrated solutions is sound in theory, but the execution has yet to translate into the double-digit growth that institutional investors typically demand.
Looking ahead, the medical device sector remains sensitive to interest rate environments and hospital staffing levels, both of which impact the volume of procedures and the ability of blood centers to operate at full capacity. Analysts will be closely watching Haemonetics’ upcoming quarterly reports for signs of stabilization in its plasma collection segment and any updates on its hemostasis management portfolio. For Invenomic, the exit from HAE and the doubling down on Viatris and Dentsply Sirona suggests a tactical move toward companies with stronger free cash flow and more defensive market positions. This portfolio rebalancing highlights the ongoing volatility in the medtech space and the importance of active management in navigating a sector where performance can vary wildly between sub-industries.
How we covered this story
Every story in our biotech coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the biotech space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled biotech-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |